Memantine for the treatment of frontotemporal dementia: a meta-analysis

Taro Kishi, Shinji Matsunaga, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan Background: There is no conclusive evidence supporting the efficacy of memantine in frontotemporal dementia (FTD). We conducted a comprehensive meta-analysis of memantine...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kishi T, Matsunaga S, Iwata N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/dd83ed873e184510ba2f258a527f8d02
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dd83ed873e184510ba2f258a527f8d02
record_format	dspace
spelling	oai:doaj.org-article:dd83ed873e184510ba2f258a527f8d022021-12-02T06:19:43ZMemantine for the treatment of frontotemporal dementia: a meta-analysis1178-2021https://doaj.org/article/dd83ed873e184510ba2f258a527f8d022015-11-01T00:00:00Zhttps://www.dovepress.com/memantine-for-the-treatment-of-frontotemporal-dementia-a-meta-analysis-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Taro Kishi, Shinji Matsunaga, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan Background: There is no conclusive evidence supporting the efficacy of memantine in frontotemporal dementia (FTD). We conducted a comprehensive meta-analysis of memantine concerning the efficacy and tolerability of memantine in FTD.Methods: Studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations up to April 10, 2015. Outcomes were Clinical Global Impression (primary), Mini-Mental State Examination, Neuropsychiatric Inventory, and Zarit Burden Interview scores as well as all-cause discontinuation. Standardized mean difference and risk ratio with 95% confidence interval were calculated.Results: Two randomized controlled trials (RCTs) (total n=130) met the inclusion criteria. Memantine was marginally superior to placebo as assessed by the Clinical Global Impression scores (standardized mean difference =-0.34, 95% confidence interval =-0.68–0.01, P=0.06). However, there were no significant differences in Mini-Mental State Examination, Neuropsychiatric Inventory, and Zarit Burden Interview scores as well as all-cause discontinuation between memantine and placebo.Conclusion: Our results suggest that memantine may benefit FTD patients. However, because only two randomized controlled trials have addressed this issue, further studies using larger samples are needed. Keywords: frontotemporal dementia, memantine, meta-analysis, Clinical Global ImpressionKishi TMatsunaga SIwata NDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 2883-2885 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Kishi T Matsunaga S Iwata N Memantine for the treatment of frontotemporal dementia: a meta-analysis
description	Taro Kishi, Shinji Matsunaga, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan Background: There is no conclusive evidence supporting the efficacy of memantine in frontotemporal dementia (FTD). We conducted a comprehensive meta-analysis of memantine concerning the efficacy and tolerability of memantine in FTD.Methods: Studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations up to April 10, 2015. Outcomes were Clinical Global Impression (primary), Mini-Mental State Examination, Neuropsychiatric Inventory, and Zarit Burden Interview scores as well as all-cause discontinuation. Standardized mean difference and risk ratio with 95% confidence interval were calculated.Results: Two randomized controlled trials (RCTs) (total n=130) met the inclusion criteria. Memantine was marginally superior to placebo as assessed by the Clinical Global Impression scores (standardized mean difference =-0.34, 95% confidence interval =-0.68–0.01, P=0.06). However, there were no significant differences in Mini-Mental State Examination, Neuropsychiatric Inventory, and Zarit Burden Interview scores as well as all-cause discontinuation between memantine and placebo.Conclusion: Our results suggest that memantine may benefit FTD patients. However, because only two randomized controlled trials have addressed this issue, further studies using larger samples are needed. Keywords: frontotemporal dementia, memantine, meta-analysis, Clinical Global Impression
format	article
author	Kishi T Matsunaga S Iwata N
author_facet	Kishi T Matsunaga S Iwata N
author_sort	Kishi T
title	Memantine for the treatment of frontotemporal dementia: a meta-analysis
title_short	Memantine for the treatment of frontotemporal dementia: a meta-analysis
title_full	Memantine for the treatment of frontotemporal dementia: a meta-analysis
title_fullStr	Memantine for the treatment of frontotemporal dementia: a meta-analysis
title_full_unstemmed	Memantine for the treatment of frontotemporal dementia: a meta-analysis
title_sort	memantine for the treatment of frontotemporal dementia: a meta-analysis
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/dd83ed873e184510ba2f258a527f8d02
work_keys_str_mv	AT kishit memantineforthetreatmentoffrontotemporaldementiaametaanalysis AT matsunagas memantineforthetreatmentoffrontotemporaldementiaametaanalysis AT iwatan memantineforthetreatmentoffrontotemporaldementiaametaanalysis
_version_	1718399964873228288

Memantine for the treatment of frontotemporal dementia: a meta-analysis

Ejemplares similares